AZD5335 targets folate receptor alpha on tumor cells, is internalized, and releases a camptothecin payload that inhibits topoisomerase I, causing DNA damage and apoptosis. Killing is directed by FRα expression; DNA topoisomerase I is the intracellular payload target, not the direct targeting antigen.